Browse studies, page 410
Page 410 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Potassium-competitive Acid Blockers for Treatment of Extraesophageal Symptoms and Signs Journal of neurogastroenterology and motility, 2025
- Effects of Tegoprazan, Potassium-Competitive Acid Blocker, on the Gastric Emptying and Postprandial Symptoms in Healthy Humans Digestive diseases and sciences, 2025
- Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan-based concomitant and bismuth quadruple therapies: A real-world evidence Journal of gastroenterology and hepatology, 2025
- Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System Current therapeutic research, clinical and experimental, 2025
- Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study The Journal of infectious diseases, 2026
- Systematic Druggable Genome-Wide Analysis Identifies Therapeutic Targets for Aging: A Mendelian Randomization Study Health science reports, 2026
- Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Network Meta-Analysis Gastro hep advances, 2025
- Effect of Tegoprazan on Tacrolimus and Mycophenolate Levels in Kidney Transplant Recipients: A Randomized Controlled Study Using a Smart Trial Platform Pharmaceuticals (Basel, Switzerland), 2025
- High Eradication Rate of a Potassium-Competitive Acid Blocker-Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real-World Study Helicobacter, 2026
- Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication of Helicobacter pylori: A Meta-Analysis of Randomized Controlled Trials JGH open : an open access journal of gastroenterology and hepatology, 2025
- Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker Advances in therapy, 2025
- Comparative renal safety: potassium-competitive acid blockers vs proton pump inhibitors Clinical kidney journal, 2026
- The Structure Determination of Tegoprazan((S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-formamide) Polymorphs A and B by Laboratory X-Ray Powder Diffraction 2025
- Efficacy and safety of on-demand tegoprazan therapy in gastroesophageal reflux disease: A multicentre, double-blind, randomised, active-controlled pilot study Research Square, 2024
- Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using 14C-radiolabelled techniques Expert opinion on drug metabolism & toxicology, 2025
- Long-term Effects of Potassium-competitive Acid Blockers and Proton Pump Inhibitors on Gastrin, Gastric Emptying Rate, and Small Intestinal Microbiota in Rats Journal of neurogastroenterology and motility, 2025
- A Novel UPLC-MS/MS Method for Determining Tegoprazan in Rat Plasma: An Application in a Rat Pharmacokinetic Study Biomedical chromatography : BMC, 2025
- Fourteen-and Ten-Day Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication-A Noninferiority, Multicenter, Randomized Controlled Trial Journal of gastroenterology and hepatology, 2026
- Evaluation of the Safety and Efficacy of K-CAB (Tegoprazan) as Symptomatic Maintenance Therapy in Patients With NERD: A Multicenter, Randomized Double-Blinded Controlled Trial The Korean journal of helicobacter and upper gastrointestinal research, 2025
- Efficacy and safety of potassium-competitive acid blockers in eradicating Helicobacter pylori and treating gastro-esophageal reflux disease: A systematic review and meta-analysis Caspian journal of internal medicine, 2026
- Protonation of Key Acidic Residues Reveals Binding Features of PCABs to Gastric H, K-ATPase The Journal of membrane biology, 2026
- Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials EClinicalMedicine, 2026
- Pharmacokinetics of the potassium-competitive acid blocker tegoprazan administered by the oral route in healthy Mexicans International journal of clinical pharmacology and therapeutics, 2026
- Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppression Journal of gastroenterology, 2026
- Randomized controlled trial comparing 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication Medicine, 2026
- Potassium-Competitive Acid Blockers for First-Line Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis Gastro hep advances, 2026
- Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials Journal of gastroenterology and hepatology, 2026
- Potassium-Competitive Acid Blockers as a New Frontier in Acid-Related Disorders and the Role of South Korean Pharmacological Innovation Pharmaceuticals (Basel, Switzerland), 2026
- CKD risk with tegoprazan versus proton pump inhibitors Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026
- Pharmacokinetic and Pharmacodynamic Characteristics of Tegoprazan According to Helicobacter pylori Infection Status Journal of gastroenterology and hepatology, 2026
- The TOP ‐ GERD Trial: Comparative Efficacy of Tegoprazan Versus Pantoprazole in the Treatment of Erosive Oesophagitis in a Non‐Asian Population Alimentary pharmacology & therapeutics, 2026
- Efficacy and Safety of Tegoprazan Combined with High-Dose Amoxicillin Dual Therapy versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Prospective Cohort Study 2026
- Rapid health technology assessment of tegoprazan in the treatment of acid-related diseases Research Square, 2026
- Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study Journal of neurogastroenterology and motility, 2024
- Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease The Journal of pharmacology and experimental therapeutics, 2019
- Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication The Korean journal of helicobacter and upper gastrointestinal research, 2023
- Review article: potassium-competitive acid blockers for the treatment of acid-related disorders Alimentary pharmacology & therapeutics, 2021
- Comparison of the Efficacy Between the Dual Therapy of Tegoprazan and the Quadruple Therapy of Tegoprazan: A Randomized Controlled Multicenter Study Clinical and translational gastroenterology, 2024
- The Effect of Tegoprazan for Prevention of Iatrogenic Ulcer Bleeding after Endoscopic Submucosal Dissection: A Noninferiority Randomized Clinical Trial Gut and liver, 2026
- Tegoprazan-based dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, open-label, non-inferiority, randomized controlled trial Scientific reports, 2026
- How ligands modulate the gastric H,K-ATPase activity and its inhibition by tegoprazan The Journal of biological chemistry, 2024
- Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment BMC gastroenterology, 2025
- Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori Gut and liver, 2021
- Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial Clinical drug investigation, 2024
- Intravenous proton pump inhibitors vs oral potassium competitive acid blockers before endoscopic treatment of bleeding peptic ulcers World journal of gastrointestinal endoscopy, 2025
- 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence Journal of gastroenterology and hepatology, 2022
- Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2022
- Vonoprazan Versus Tegoprazan-Amoxicillin Dual Therapy for Treatment-Naïve Patients With Helicobacter pylori Infection: A Prospective, Multicenter, Open-Label, Randomized Controlled Study Helicobacter, 2026
- Comparator Choice in Helicobacter pylori Eradication: Tegoprazan-Amoxicillin Dual Therapy Versus an Optimized Bismuth-Containing Quadruple Therapy in a Randomized Trial and Meta-Analysis International journal of antimicrobial agents, 2026
- Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study Gut and liver, 2023
- Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy Scientific reports, 2024
- Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function Frontiers in immunology, 2022
- The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study The Korean journal of helicobacter and upper gastrointestinal research, 2025
- Prescription trends of gastric acid suppressants and association with potential adverse events in Korea: a real-world cross-sectional study Therapeutic advances in gastroenterology, 2025
- Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China Therapeutic advances in gastroenterology, 2025
- Comprehensive Investigation of Polymorphic Stability and Phase Transformation Kinetics in Tegoprazan Pharmaceutics, 2025
- Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication The Korean journal of helicobacter and upper gastrointestinal research, 2024
- Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial Neurogastroenterology and motility, 2025
- Tegoprazan to treat gastroesophageal reflux disease Drugs of today (Barcelona, Spain : 1998), 2020
- Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers Clinical and translational science, 2021
- Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial Helicobacter, 2026
- Seven-Day Versus 14-Day Tegoprazan and Tetracycline-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Randomized, Open-Label, Noninferiority Trial Helicobacter, 2025
- Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole Clinical pharmacokinetics, 2023
- Structure Determination of Tegoprazan((S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-formamide) Polymorphs A and B by Laboratory X-Ray Powder Diffraction Molecules (Basel, Switzerland), 2025
- Comprehensive Analysis of Factors Associated With Helicobacter pylori Eradication Therapy The Korean journal of helicobacter and upper gastrointestinal research, 2024
- Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease Expert opinion on drug metabolism & toxicology, 2025
- Efficacy and safety of tegoprazan (LXI-15028) vs . esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial Chinese medical journal, 2025
- Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed-release formulations British journal of clinical pharmacology, 2023
- Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects Translational and clinical pharmacology, 2023
- Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication Journal of personalized medicine, 2022
- Comparison of tegoprazan-based and proton pump inhibitor-based regimens for Helicobacter pylori eradication: a meta-analysis and systematic review Frontiers in medicine, 2025
- Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects Journal of clinical pharmacology, 2021
- A systematic review and meta-analysis of randomized controlled trials: the effect of potassium-competitive acid blockers on nighttime symptoms of gastroesophageal reflux disease Esophagus : official journal of the Japan Esophageal Society, 2026
- The first case of tegoprazan-induced urticaria Journal of clinical pharmacy and therapeutics, 2020
- Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study Journal of clinical medicine, 2023
- PPIs Have It: Does Tegoprazan Affect Gastric Emptying and Produce Dyspeptic Symptoms? Digestive diseases and sciences, 2025
- Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection Clinical and translational gastroenterology, 2023
- Efficacy and Safety of Tegoprazan in Helicobacter pylori Eradication: An Umbrella Review of Meta-Analyses Pharmaceuticals (Basel, Switzerland), 2026
- Carcinogenicity assessment of tegoprazan in Sprague-Dawley (Crl:CD) rats and ICR (Crl:CD1) mice Regulatory toxicology and pharmacology : RTP, 2023
- Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators Pharmaceutics, 2023
- Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects Frontiers in pharmacology, 2021
- Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects Clinical therapeutics, 2022
- Efficacy of Potassium-Competitive Acid Blockers in Functional Dyspepsia: A Systematic Review and Meta-Analysis Gastroenterology research, 2025
- Tegoprazan vs. proton pump inhibitors for erosive esophagitis: a superior alternative or just another option? A systematic review and meta-analysis of randomized controlled trials European journal of gastroenterology & hepatology, 2025
- Tegoprazan and low- or high-dose amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication (TREAT): protocol for a multicenter, open-label, non-inferiority, randomized controlled trial Therapeutic advances in gastroenterology, 2025
- Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation Pharmaceutics, 2021
- Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication The Korean journal of internal medicine, 2023
- P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis Therapeutic advances in gastroenterology, 2024
- Tegoprazan and the risk of end-stage kidney disease progression: a nationwide Korean study Kidney research and clinical practice, 2026
- Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial Chinese medical journal, 2025
- Characterisation of degradation products of tegoprazan by LC-MS and GC-MS. Journal of pharmaceutical and biomedical analysis, 2023
- Comparing Proton Pump Inhibitors and Emerging Acid-Suppressive Therapies in Gastroesophageal Reflux Disease: A Systematic Review Cureus, 2025
- Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy for ESD induced gastric ulcers a randomized multicenter study Scientific reports, 2025
- Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China Helicobacter, 2024
- History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs The Korean journal of helicobacter and upper gastrointestinal research, 2023
- Tegoprazan-Amoxicillin Dual Therapy for Clarithromycin-Resistant Helicobacter pylori: A Feasibility Pilot Study Microorganisms, 2025
- The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study Gut and liver, 2024
- Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial Helicobacter, 2024
- Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects Clinical therapeutics, 2021
- Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial Helicobacter, 2026
